



PRESS RELEASE

## **Wolters Kluwer acquires online healthcare courseware provider IntelliLearn**

**Waltham — May 30, 2025 —** [Wolters Kluwer Health](#) today announced it has acquired [IntelliLearn Pty Ltd.](#), a provider of online courseware solutions for nursing schools in Australia and the U.S. IntelliLearn will become part of Wolters Kluwer's Health, Learning, Research & Practice (HLRP) business, a leader in nursing education and practice solutions.

"We're pleased to be adding the IntelliLearn solutions to our Lippincott suite of nursing products," said [Julie Stegman](#), **Vice President and General Manager, Wolters Kluwer Health, Learning & Practice**. "The IntelliLearn solutions, including medication safety and other medical math content, allow us to offer an even broader range of training modules to prepare nursing students for practice."

Founded in 2010 and based in Adelaide, Australia, IntelliLearn's cloud-based solutions are used by educational institutions in Australia, New Zealand, Canada, and the U.S. The company brings seven full-time employees to Wolters Kluwer Health as well as a network of contract workers. The acquisition is expected to reach a return on invested capital (ROIC) above our weighted after-tax cost of capital (WACC) within three to five years and to have an immaterial impact on Wolters Kluwer adjusted earnings.

###

### **About Wolters Kluwer**

Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.

Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX, Euro Stoxx 50 and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information, visit [www.wolterskluwer.com](http://www.wolterskluwer.com), follow us on [LinkedIn](#), [Facebook](#), [YouTube](#) and [Instagram](#).

### **Media**

Stefan Kloet  
Associate Director  
Global Communications  
[press@wolterskluwer.com](mailto:press@wolterskluwer.com)  
m: +31 612 223 657

### **Investors/Analysts**

Meg Geldens  
Vice President  
Investor Relations  
[ir@wolterskluwer.com](mailto:ir@wolterskluwer.com)

**Forward-looking Statements and Other Important Legal Information**

This report contains forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer’s businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.